Thomas Flaig, M.D. Assistant Professor Education: University of Minnesota, June 1999 University of Colorado Denver School of Medicine Division of Medical Oncology Tel: (303) 724-3808 Fax: (303) 724-3889 e-mail: thomas.flaig@uchsc.edu Bio Dr. Flaig completed his fellowship in 2005 at the University of Colorado Denver, after which he joined the faculty of the Divison of Medical Oncology at the University of Colorado Denver, Aurora, CO. Research Dr. Flaig is focused on translational genitourinary cancer research, with an emphasis on prostate and bladder cancer.  He is a graduate of the University of Minnesota School of Medicine and completed the hematology/oncology fellowship program at the University of Colorado in 2006.  The GU oncology clinic actively participates in cooperative (SWOG) and industry-sponsored clinical trials.  Dr. Flaig has recently reported on a local, investigator-initiated phase I trial of silibinin in prostate cancer patients, with a follow-up NIH-sponsored silibinin biomarker study now underway.  His laboratory effort is split between new prostate cancer treatment approaches using natural products and the integration of targeted therapies into the treatment of bladder cancer.

FACULTY LIST Lynn Bemis Virginia Borges Paul Bunn David Calverley Ross Camidge Dan Chan Gail Eckhardt Anthony Elias Thomas Flaig Marileila Garcia L. Michael Glode Rene Gonzalez Barb Helfrich Fred Hirsch Christopher Hogan Antonio Jimeno Madeleine Kane Choon-Kee Lee Stephen Leong Wells Messersmith Han Myint Ana Oton Peter Raich William Robinson Pepper Schedin John Tentler William Tse Colin Weekes

Publications
Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM.  A Phase II Trial of Dexamethasone, Vitamin D and Carboplatin in Patients with Hormone Refractory Prostate Cancer.  Cancer.  2006; 107(2):266-274.

Bowles DW, Flaig TW.  Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.  Cancer Investigation.  2006; 24(5): 517-520.

Arthur C, Flaig T, Su L, Denney R, Barnes F, Glodé LM.  The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines.  Ultrasonics.  2007; 46(1): 68-73.

Flaig TW, Gustafson DL, Su L, Zirrolli J, Harrison G, Pierson AS, Agarwal R, Glodé LM.  A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer.  Investigational New Drugs.  2007; 25(2):139-46.

Flaig TW, Nordeen SK, Lucia S, Harrison G, and Glodé LM.  Conference Report: Current status of biomarkers potentially associated with prostate cancer outcomes. Journal of Urology.  2007; 177(4):1229-37.

Flaig TW, Su Lih-Jen, Agarwal R, Glodé LM.  Silibinin synergizes with mitoxantrone to inhibit cell growth via apoptosis in prostate cancer cells.  International Journal of Cancer.  2007; 120(9): 2028-33. 

PubMed articles

BACK TO TOP